Effects of CYP2C9 and VKORC1 on INR Variations and dose Requirements During Initial Phase of Anticoagulant Therapy

10.1097/01.mbc.0000174079.47248.0c

10.1056/NEJMoa035029

10.1378/chest.114.5_Supplement.445S

10.1126/science.286.5439.487

10.2165/00003088-200140080-00003

10.1097/00008571-200401000-00003

10.2165/00003088-200544120-00003

Thijssen HH , FlinoisJP, BeaunePH: Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.Drug Metab. Dispos.28 , 1284–1290 (2000).

10.1097/00008571-199402000-00005

10.1097/00008571-199608000-00007

10.1055/s-0037-1616248

10.1097/00008571-200011000-00010

10.1016/j.clpt.2004.01.008

10.1016/j.clpt.2003.12.017

10.1182/blood.V99.11.4237

Tassies D , FreireC, PijoanJ et al.: Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Haematologica87 , 1185–1191 (2002).

10.1046/j.1538-7836.2003.00442.x

10.1038/sj.tpj.6500258

10.1038/nature02254

10.1038/nature02214

10.1056/NEJMoa044503

10.1160/TH05-04-0290

10.1038/sj.tpj.6500313

10.1182/blood-2005-03-1108

10.1016/j.clpt.2005.11.011

10.1007/s10038-005-0354-5

10.3121/cmr.2007.724

10.1182/blood-2005-01-0341

10.1016/j.clpt.2006.04.006

10.1111/j.1538-7836.2007.02630.x

10.1056/NEJMoa0708078

Manotti C , MoiaM, PalaretiG, PengoV, RiaL, DettoriAG: Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment).Haematologica86 , 1060–1070 (2001).

10.1093/nar/16.3.1215

10.1182/blood.V96.5.1816

10.1182/blood-2004-06-2111

10.1160/TH03-06-0379

10.1055/s-0038-1651587

10.1111/j.1538-7836.2006.02039.x

10.1016/j.ajhg.2007.10.002

10.1182/blood-2006-08-038984

10.1093/hmg/ddi180

10.1038/clpt.2008.10

10.1038/sj.clpt.6100290

10.1001/jama.287.13.1690

10.1055/s-0037-1614114

10.1007/s11239-007-0104-y

10.1111/j.0902-4441.2006.t01-1-EJH2957.x

10.1007/s11239-006-9030-7

10.1038/sj.clpt.6100084

10.1007/s00439-006-0260-8

10.1097/01.fpc.0000184955.08453.a8

10.1016/j.clpt.2006.06.009

10.1160/TH04-08-0542

10.1182/blood-2007-01-069609

10.1161/CIRCULATIONAHA.107.737312

National Heart Lung and Blood Institute. Clinical trials. (Accessed July 2008) http://rt5.cceb.med.upenn.edu/warfdcc/WARF-1.html